Daily Health Headlines

Smog May Shorten Lives of Lung Cancer Patients

👤by HealthDay 0 comments 🕔Friday, August 5th, 2016

FRIDAY, Aug. 5, 2016 (HealthDay News) -- Air pollution may shorten the lives of lung cancer patients, a new study suggests.

Researchers led by Sandrah Eckel, who's with the department of preventive medicine at the University of Southern California in Los Angeles, analyzed data from more than 352,000 people in California who were diagnosed with lung cancer between 1988 and 2009.

Higher exposure to the pollutants nitrogen dioxide, ozone and airborne particles was associated with an increased risk of early death. The association was strongest in patients with early stage disease, particularly adenocarcinoma, which accounts for 80 percent of lung cancer cases, the researchers said.

Early stage patients with greater exposure to pollutants survived on average 2.4 years compared to 5.7 years for those with low exposure, the study found.

The study was published online Aug. 4 in the journal Thorax.

Since this was an observational study, no firm conclusion can be drawn about cause and effect, the researchers said. But they noted that the International Agency for Research on Cancer classifies air pollution as a cancer-causing agent.

"This study, along with two other previously published analyses on the impact of air pollution on cancer survival, provide compelling initial evidence that air pollution may be a potential target for future prevention and intervention studies to increase cancer survival," Dr. Jaime Hart wrote in an accompanying journal editorial.

Hart is an epidemiologist at Brigham and Women's Hospital in Boston.

-- Robert Preidt

Article Credits / Source

HealthDay

HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCE: Thorax, news release, Aug. 4, 2016

View More Articles From HealthDay 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Cancer Articles

No Benefit From Routine Thyroid Cancer Screening: Task Force

No Benefit From Routine Thyroid Cancer Screening: Task Force0

TUESDAY, Nov. 22, 2016 (HealthDay News) -- Doctors should not screen for thyroid cancer in patients who have no symptoms of the disease, according to a U.S. Preventive Services Task Force draft recommendation. It reaffirms a recommendation ...

Depressed Women Less Likely to Get Best Breast Cancer Care: Study

Depressed Women Less Likely to Get Best Breast Cancer Care: Study0

FRIDAY, Nov. 18, 2016 (HealthDay News) -- Breast cancer patients with a history of depression are less likely to receive recommended care for their disease, a new study finds. The study included more than 45,000 Danish women diagnosed with ...

Earnings Fall After a Child's Cancer Diagnosis

Earnings Fall After a Child's Cancer Diagnosis0

MONDAY, Nov. 21, 2016 (HealthDay News) -- After a child's cancer diagnosis, parents' income often drops and mothers frequently stop working, a new study finds. Moreover, the financial effects of a cancer diagnosis can last years, with mothers' ...

Monoclonal Antibodies

Monoclonal Antibodies0

home / cancer center / cancer a-z list / monoclonal antibodies index / monoclonal antibodies drug monograph Pharmacy Author: Omudhome Ogbru, PharmD Omudhome Ogbru, PharmDDr. Ogbru received his ...

New Drug May Brighten Outlook for Advanced Breast Cancer

New Drug May Brighten Outlook for Advanced Breast Cancer0

WEDNESDAY, Nov. 16, 2016 (HealthDay News) -- A recently approved drug can help slow the progression of advanced breast cancer, a new clinical trial confirms. The drug, called palbociclib (Ibrance), was approved in the United States last year ...

View More Cancer Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!